← Back to patent-cliff list

Quisinostat Hydrochloride

Tier C — Watch / trade

Quisinostat Hydrochloride

Johnson & Johnson Innovative Medicine
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:HDAC1

Indications (approved):葡萄膜黑素瘤, Glioblastoma, Plasmodium infection, Myelodysplastic syndrome, Ovarian cancer, Cutaneous T-cell lymphoma, Non-small cell lung cancer, Epithelial ovarian cancer

Regional status

US
Phase II
2011-11-01
EU
No progress
2011-11-01
China
Phase I
2025-06-03
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 0Optimised (non-patent) × 1Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OptimisedRoute 1Steps 5 · Total yield 0.31 g
QUISIN-0066723-30-4QUISIN-007875318-41-5QUISIN-001603954-49-0QUISIN-00219012-03-4QUISIN-003—QUISIN-004875318-39-1QUISIN-005875318-40-4API · Quisinostat Hydrochloride
CodeCAS No.Intermediate
QUISIN-0066723-30-4O-(tetrahydro-2H-pyran-2-yl)hydroxylamine
QUISIN-007875318-41-52-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)-N-((tetrahydro-2H-pyran-2-yl)oxy)pyrimidine-5-carboxamide
QUISIN-001603954-49-0ethyl 2-(4-(aminomethyl)piperidin-1-yl)pyrimidine-5-carboxylate
QUISIN-00219012-03-41-methyl-1H-indole-3-carbaldehyde
QUISIN-003-(E)-ethyl 2-(4-((((1-methyl-1H-indol-3-yl)methylene)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxylate
QUISIN-004875318-39-1ethyl 2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxylate
QUISIN-005875318-40-4sodium 2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxylate

Frequently asked questions

What are the approved indications of Quisinostat Hydrochloride?

Approved indications include: 葡萄膜黑素瘤, Glioblastoma, Plasmodium infection, Myelodysplastic syndrome, Ovarian cancer, Cutaneous T-cell lymphoma, Non-small cell lung cancer, Epithelial ovarian cancer.

When does the Quisinostat Hydrochloride patent expire?

No public expiry year is available for Quisinostat Hydrochloride yet; this page updates once verified.

How many synthesis routes are recorded for Quisinostat Hydrochloride?

1 synthesis routes are recorded; the shortest is 5 steps with 0.31 g total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Quisinostat Hydrochloride intermediates?

All intermediates in Quisinostat Hydrochloride routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Quisinostat Hydrochloride intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-19